MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtho.2018.04.032

Медицинская библиотека · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

Burt Bryan M, Richards William G, Lee Hyun-Sung, Bartel Sylvia, Dasilva Marcelo C, Gill Ritu R, Jaklitsch Michael T, Johnson Bruce E, Swanson Scott J, Bueno Raphael, Sugarbaker David J

Клиническое исследование I фазыСтатьяПеревод в очереди

Аннотация

INTRODUCTION

The primary objective of this single-institution phase I clinical trial was to establish the maximum tolerated dose of gemcitabine added to cisplatin and delivered as heated intraoperative chemotherapy after resection of malignant pleural mesothelioma.

METHODS

The extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators' assessment of patient fitness and potential for macroscopic complete resection. Previously established intracavitary dosing of cisplatin (range 175-225 mg/m2) with systemic cytoprotection was used in combination with escalating doses of gemcitabine, following a 3-plus-3 design from 100 mg/m2 in 100-mg increments.

RESULTS

From 2007 to 2011, 141 patients were enrolled and 104 completed treatment. The median age of those completing treatment was 65 years (range 43-85 years), and 22 (21%) were female. In the EPP arm (n = 59), 31 patients (53%) had the epithelioid histologic type and the median radiographic tumor volume was 236 cm3 (range 16-4285 cm3). In the P/D arm (n = 41), 29 patients (71%) had the epithelioid histologic type and the median tumor volume was 79 cm3 (range 6-1107 cm3). The operative mortality rate was 2%, and 35 and 22 serious adverse events were encountered among 27 patients (46%) and 16 patients (39%) in the EPP and P/D arms, respectively. Dose-limiting toxicity (grade 3 leukopenia) was observed in two patients who were receiving 1100 mg/m2 of gemcitabine, thus establishing the maximum tolerated dose at 1000 mg/m2, in combination with 175 mg/m2 of cisplatin. The median overall and recurrence-free survival times in treated patients were 20.3 and 10.7 months, respectively.

CONCLUSIONS

Combination cisplatin and gemcitabine heated intraoperative chemotherapy can be administered safely and feasibly in the context of complete surgical resection of malignant pleural mesothelioma by EPP or P/D.

Для цитирования: Burt Bryan M, Richards William G, Lee Hyun-Sung, Bartel Sylvia, Dasilva Marcelo C, Gill Ritu R, Jaklitsch Michael T, Johnson Bruce E, Swanson Scott J, Bueno Raphael, Sugarbaker David J. A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018. DOI: 10.1016/j.jtho.2018.04.032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.